

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 9/96, G01N 33/68, 33/531		A1	(11) International Publication Number: WO 96/27661 (43) International Publication Date: 12 September 1996 (12.09.96)
(21) International Application Number: PCT/US96/03034 (22) International Filing Date: 6 March 1996 (06.03.96)		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 08/400,158 7 March 1995 (07.03.95) US		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant: DADE INTERNATIONAL INC. [US/US]; 1717 Deerfield Road, Deerfield, IL 60015 (US).			
(72) Inventors: FLAA, Cathy; 101 Westover #303, Norfolk, VA 23507 (US). SABUCEDO, Alberto; 9899 S.W. 1st Terrace, Miami, FL 33174 (US). CHIN, Bruce; 11845 S.W. 112 Avenue Circle, Miami, FL 33176 (US). BAUER, Roger, 1225 Fairfax Court, Ft Lauderdale, FL 33326 (US).			
(74) Agents: WINSTON, Lois, K. et al.; 1717 Deerfield Road, Deerfield, IL 60015 (US).			
(54) Title: STABILIZING SOLUTIONS FOR PROTEINS AND PEPTIDES			
(57) Abstract			
<p>Disclosed are compositions for stabilizing proteins and fragments of the proteins. The composition contains buffer, salt, reducing agents, chelating agents and stabilizing proteins. The composition may be used to prepare highly stable diagnostic calibrators or controls and is particularly useful for calibrators or controls for cardiac markers such as troponin.</p> <p style="text-align: right;">copy file</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

Stabilizing Solutions for Proteins and Peptides

Field of the Invention

The present invention relates generally to aqueous
5 solutions to stabilize proteins and peptides. In particular
this invention relates to aqueous calibrator and control
solutions for diagnostic assays for proteins and peptides,
particularly: troponin, myoglobin, CK, CK isoenzymes, LD, LD
isoenzymes and myosin, and fragments thereof and most
10 particularly troponin and troponin fragments including
synthetic and recombinant peptides of troponin.

Background of the Invention

A number of physiological conditions and states are
15 associated with increased levels of CK-MB, myoglobin, myosin
and troponin. Elevated levels generally are associated with
myocardial infarction and other conditions which result in
myocardial injury.

Principally because of the association of increased
20 levels of these proteins with acute myocardial infarction,
tests for acute myocardial infarction (AMI) have been or are
being devised to determine the level of these proteins in
bodily fluids. Thus, these proteins have become known as
cardiac markers.

25 Acute myocardial infarction continues to be a major cause
of illness and death, particularly in the United States. An
estimated 1.5 million admissions to hospitals can be
attributed to suspected myocardial infarction or

related cardiac disease. Of these patients, only roughly 25% are actually suffering an AMI while another 30% are admitted with unstable angina, 20% have stable coronary artery disease (CA), and the remaining 25% have no CAD. Differentiation of
5 those patients who require immediate care and hospitalization from those who are not in danger is of great value in providing effective medical care, reducing hospitalization costs, and effectively managing hospital facilities. Current studies indicate that early intervention is critical for
10 optimum therapeutic measures.

These therapeutic measures have the potential to restore blood flow to the damaged myocardium, limit the size of the infarct, and thus preserve cardiac function. New therapeutic intervention mechanisms, specifically thrombolytic agents such
15 as streptokinase and tissue plasminogen activator are available to restore coronary artery blood flow and reduce the incidence of morbidity. Most clinicians believe that intervention must take place as soon as possible and should be well within the first four hours after the onset of chest
20 pain.

Thus, an ideal cardiac marker or combination of markers should be cardiac tissue specific, it should be diagnostic within four hours after the onset of AMI, it should remain somewhat elevated for at least seven days after AMI but it
25 should detect reinfarction even during the first few days of the first AMI.

Diagnosis of AMI is now based on an abnormal electrocardiogram (ECG), clinical symptoms and history, and

elevated cardiac enzyme levels. Currently, CKMB is often used as the "definitive" serum marker for AMI.

However, often the ECG and clinical presentation give inconclusive or conflicting predictions of cardiac trauma.

- 5 CK-MB testing has some limitations in contributing to final diagnosis. Skeletal muscle damage and strenuous exercise can artificially elevate CK-MB levels and confuse the clinical picture. In addition, CK-MB does not become diagnostically elevated until 4-6 hours after AMI. In addition, CK-MB levels
10 become non-diagnostic 48-72 hours after AMI.

- CK-MB has been prepared in a control solution to monitor diagnostic measurements of this analyte, however CK-MB is an enzyme which has limited stability in human serum and common buffered aqueous solutions. U.S. Patent No. 4,994,375
15 discloses a stable reconstituted aqueous based control. Currently there are immunoassay kits, such as the Dade® Stratus® CK-MB Fluorometric Enzyme Immunoassay Kit available on the market for the determination of CK-MB levels. Many of these kits include calibrators. Control solutions containing
20 CK-MB, such as the Dade® CK-MB/Myoglobin Immunoassay Control, are also commercially available.

- Myoglobin is a marker present in both skeletal and cardiac muscle. Myoglobin levels are elevated within 2 hours of AMI. The serum level peaks in 6-8 hours but returns to
25 non-diagnostic levels after 24-36 hours. However, serum myoglobin levels are also increased after skeletal muscle injury. There are a few immunoassay kits,

such as the Dade® Stratus® Myoglobin Fluorometric Enzyme Immunoassay Kit for the determination of myoglobin levels, that are commercially available. Myoglobin containing control solutions have been prepared and are commercially available
5 from such sources as Dade® CK-MB/Myoglobin Immunoassay Control.

Troponin is a protein complex having a molecular weight of about 85 kD that performs the regulatory function of the contractile mechanism of the muscle tissue. The amino acid sequences of subunits which comprise the troponin complex has been determined. See, for instance, Vallins W.J. et al., Molecular cloning of human cardiac troponin I using polymerase chain reaction, FEBS LETTERS :Vol. 270, number 1, 2 September 1990. Troponin is composed of three subunits of similar
10 molecular weight, which, in the presence of calcium, cooperate to control either the contraction or relaxation of the muscle. The three subunits are designated troponin T, C, and I. Both the T and I molecules contained in heart muscle have amino acid sequences which are cardiac specific. Thus, both
15 troponin T and troponin I have potential for superior specificity in testing for damage of myocardial origin. Damage to cardiac tissue causes these contractile proteins to be released into circulation fairly rapidly after injury providing the potential for sensitivity as well. Troponin is
20 diagnostic 4-6 hours after AMI and remains elevated for 4-14 days.
25

Proteins of the contractile apparatus such as troponin are part of an insoluble protein complex. Thus, when

- purified troponin is placed in serum it is difficult to solubilize. In addition, purified preparations of troponin tend to be very labile and apparent changes in its conformation and/or adhesion to container surfaces tend to
- 5 complicate quantification of the molecule. Thus, it is very difficult to design an aqueous solution which stabilizes troponin. Currently commercially available calibrators and controls used for diagnostic assays for troponin have very limited stability in liquid form.
- 10 Thus a need exists for aqueous solutions useful for solubilizing and stabilizing troponin. Such solutions can function as a diagnostic control or calibrator matrix for troponin and other cardiac markers or other proteins that are difficult to solubilize and/or stabilize. In addition, the
- 15 matrix is useful for storing the protein(s).
- Several criteria need to be met when formulating a calibrator or control base for troponin or other proteins that have stability or solubility issues similar to troponin. Stability issues are of primary concern. Liquid products are
- 20 preferred for reproducibility and ease of use and should be stable. However if the product is lyophilized, it should be stable after reconstitution. Previous troponin calibrators are based on human serum derived products and contribute very little to the stability of the composition. For instance, the
- 25 published "dating" of human serum based lyophilized troponin T calibrators and controls of the Boehringer Mannheim Elisa-Test® Troponin T after reconstitution is only 6 hours at 2 to 8 C and 3

months when aliquoted and stored at -20 C. A matrix which increases the stability of the product is highly desirable.

Moreover, use of normal or processed human serum presents health issues to both clinicians and manufacturers. Thus, a 5 matrix which lowers health risks is also highly desirable.

The calibrators in a synthetic matrix must mimic the shape of a response curve using normal human serum. This is important to ensure that results read off a standard curve generated with the matrix are accurate when comparing the 10 results to the actual biological milieu.

In a diagnostic assay, non-specific binding of the analyte to the test surface (e.g. solid support such as test tubes, paper, slides etc.) must be minimized in order to keep calibration accurate and eliminate any risks of "discrepant" 15 results. Thus, the non-specific binding of the analyte in a matrix must be minimized and must be similar to the non-specific binding of samples. It is also important that during storage, the protein or protein fragment does not appreciably bind to the storage container.

20 There are instances when an analyte analogue may be more desirable than the actual analyte. If an analyte analogue is used instead of the analyte, the binding of the analogue must mimic the binding of the analyte. Particular care must be used when selecting analogues for proteins because the 25 immunobinding of the analogue must mimic that of the protein.

Thus, any conformational dependence of the protein for the binding site

must be maintained in the analogue. In addition, stability of the analogue should be the same or greater than that of the analyte. Again, the stability of the protein analyte may be related to its conformation. Finally, if an analogue is
5 substituted for an analyte, it is desirable that the analogue be more readily available than the analyte.

Summary of the Invention

This invention provides a stabilized clinical laboratory
10 non-human serum derived control and/or calibrator matrix to be used in performing calibration curves for diagnostic assays and for monitoring the precision and accuracy of diagnostic assays for certain unstable and/or less soluble proteins such as cardiac markers. In particular, the stabilized matrix is
15 useful for solubilizing and/or stabilizing troponin I, troponin T, CK-MB, myoglobin, myosin and fragments of these proteins or analytes.

The matrix uses a novel mixture of constituents to impart a stability to the analyte that is at least equivalent and
20 preferably better than the stability of the analyte in normal human serum. In particular, an aqueous based mixture of a buffer, albumin, gelatin, chelating agent, reducing agent and salts, all at a slightly acidic to mildly alkaline pH is used to stabilize and solubilize the analyte or analyte analogue.

25 Also disclosed are methods to prepare the matrix.

Brief Description of the Drawings

Figure 1 shows a comparison of the stability at 2-8 C of recombinant full length troponin I in various matrices.

5 Figure 2 shows a comparison of the stability at 2-8 C of a recombinantly produced 80 amino acid peptide in various matrices.

Figure 3 shows a comparison of the stability at 2-8 C of a 10 ng/mL calibrator of a synthetic peptide of troponin I in
10 various matrices.

Figure 4 shows a comparison of the stability at 2-8 C of a 50 ng/mL calibrator of a synthetic peptide of troponin I in various matrices.

Figure 5 shows a comparison of the stability at 37 C of a
15 synthetic peptide of troponin I in various matrices.

Figure 6 shows a comparison of the stability at 37 C of a synthetic peptide of troponin I in various matrices where all of the matrices include a protease inhibitor.

Figure 7 shows a calibration curve of different levels of a
20 synthetic peptide of troponin I in a matrix of the present invention.

Detailed Description of the Invention

The stabilized clinical laboratory non-human serum derived control and/or calibrator matrix for cardiac markers
25 and other unstable proteins comprises an aqueous solution of a buffer, a stabilizing protein such as albumin, ovalbumin, casein and the like, a chelating agent, a reducing agent and a salt, all at a slightly acidic to mildly alkaline pH.

The matrix can contain a blocking agent such as gelatin, detergents and protease inhibitors. A preservative may be added to prevent microbial growth. An analyte or analyte analogue such as cardiac markers or other unstable or 5 relatively insoluble proteins or fragments thereof are also added. If the calibrator or control will be lyophilized or frozen, sugars or other bulking agents are added.

The preferred buffers include buffers such as TRIS buffers and phosphate buffers. Other buffers include:

- 10 3-(N-Morpholino) propane sulfonic acid (MOPS), N-Tris-hydroxymethyl methyl-2-aminoethane sulfonic acid (TES), 3-[N-bis (hydroxyethyl)-amino] -2-hydroxypropane sulfonic acid (DIPSO), Piperazine-N, N'Bis(2)-hydroxypropane sulfonic acid (HEPPSO), Tris-(hydroxymethyl) aminoethane, N-2-
15 Hydroxyethylpiperazine-N'-2-aminoethane sulfonic acid (HEPES), 3-[N-(Tris-hydroxymethyl) methylamino] -2-hydroxy-propane sulfonic acid (TAPSO), and (2 p[2-Amino-2-oxoethyl) - amino] ethanesulfonic acid (ACES). The most preferred buffer is a phosphate such as sodium phosphate.

20 The concentration of the buffer may be from about 10 mM to 200 mM. Preferably the concentration is about 25 mM to 100 mM. Most preferably the concentration is about 50 mM.

The stabilizing protein may be albumin, ovalbumin, casein or the like. The stabilizing protein, as with the other 25 ingredients, should be essentially free of contaminants that interfere with the stability of the analyte in the matrix. Substances that may destabilize or

destroy protein structure such as proteases are examples of such contaminants. Albumin is a preferred stabilizing protein.

The source of the albumin is not critical. The albumin may be native or recombinant in origin. The most available source 5 of native albumin is of bovine origin. It is most preferred that the albumin be essentially protease-free if the protein analyte or analogue is susceptible to protease degradation. Alternatively, protease inhibitors can be added. The preferred concentration of albumin is from 5-20%, 8-12% and 10 most preferably at about 10%.

Although not wishing to be bound by any particular theory, it is believed that the protein stabilizer functions to provide a protective effect to the analyte or analyte analogue.

15 A blocking agent (i.e. an agent to minimize the non specific binding of the analyte or analyte analogue to surfaces) such as gelatin, casein, ovalbumin and the like may be added. Gelatin is the preferred blocking agent. The gelatin, if of bovine origin, is added at a concentration of 20 about 0.01 to .15%, most preferably 0.1%. If the gelatin is of a different origin (e.g. fish) the concentration is adjusted appropriately.

A chelating agent is also added. The preferred chelating agents are ethylenebis (oxyethylene nitrilio)-tetraacetic acid 25 (EGTA) and ethylene diamine tetracetic acid (EDTA), sodium citrate, or oxalate salts such as sodium, potassium, ammonium or lithium oxalate. The most preferred chelating agent is EDTA. The concentration of chelating agents may be from 1 mM to 15 mM and most preferably is from 5 to 10 mM.

The preferred reducing agent is N-acetyl-cysteine (NAC).

Examples of other reducing agents which may be used include 2-aminoethanethiol, 2-mercaptoproethanol, 2-mercaptoproethylamine and dithiothreitol.

5 The concentration of reducing agent may be from about 0 to 5 mM, preferably the reducing agent is about 2 mM to 3.5 mM, and most preferably about 2.6 mM.

The pH may be from about 5.0 to 8.0. Slightly acidic pH values lower the non-specific binding of the troponin. The 10 preferred range of pH is about 5 to 7.5 and most preferably about 7.0.

The preferred salt is sodium chloride. Many other salts may be substituted. Examples of other salts include potassium salts, ammonium salts, and lithium salts.

15 If a protease inhibitor is added, aprotinin and "Protease Inhibitor" (Sigma) are effective and may be used at the manufacturer's recommended concentration. Examples of other protease inhibitors include (2S, 3R)-3-Amino-2-hydroxy-5-methylhexanoyl]-Val-Val-Asp (Amastatin-Sigma), [2S,3R]-3-Amino-2-hydroxy-4-[4-nitrophenyl]-butanoyl-L-leucine, 20 Antipain, [2S,3R]-3-Amino-2-hydroxy-5-methylhexanoyl]-Val-Val-Asp (Epiamastatin-Sigma), [(2R,3R)-3-Amino-2-hydroxy-4-phenylbutanoyl]-L-leucine (Epibestatin-Sigma), Foroxymithine, Acetyl-Leu-Leu-Arg-al (Leupeptin-Sigma), 4-Amino-3-hydroxy-6-25 methyl-heptanoic acid, 4-Amino-3-hydroxy-6-methylheptanoic acid, N-(a-Rhamnopyranosyloxy-hydroxyphosphinyl)-Leu-Trp and phenyl methane sulfonyl fluoride (PMSF).

The preferred detergents, if added, are SDS and Triton X-100. Other detergents include Tween-20, Brij, Sorbitin,

Tergital and Nonidet. The concentration of detergents may be from 0.05% to 0.3%. The preferred range is from about 0.05% and 0.2%. The most preferred concentration is 0.1%.

The preservative may be added to prevent microbial and 5 fungal growth. The preservatives may be clotrimazole of at least 0.03%, chloramphenicol of at least 0.017%, or sodium azide of at least 0.05%. Other preservatives include gentamicin, mycostatin, thimerasol and Kathon at an effective concentration.

10 To prepare the matrix, plastics such as polypropylene should be used. This minimizes loss of proteins to glass due to non specific binding to glass. Alternatively, glass based labware can be utilized but should be siliconized prior to use.

15 If the calibrator or control matrix is to be lyophilized or frozen, bulking agents are added. The preferred bulking agents are trehalose at 3 to 10% and sucrose at about 100 mM. The most preferred concentration of trehalose is about 5-10%. Other bulking agents include glucose, sucrose, galactose, 20 manose, maltose, lactose, isomaltose, cellobiose, mannobiose, melbiose, maltotriose, nystose, maltotetraose, maltopentaose, maltohexaose, and maltoheptaose.

One liter of the matrix may be prepared by dissolving about 30 grams of BSA, about one gram of gelatin, about 15 grams of sodium chloride, 3 grams of EDTA, about 50 grams of trehalose, a preservative and a clinically appropriate level 5 of the analyte or analyte analogue in 700 ml of 0.50 mM sodium phosphate buffer. After all ingredients are dissolved the pH is adjusted to 7.0 and then a sufficient volume of a buffer, such as sodium phosphate, is added to bring the volume to 1.0 L. The solution is sterile filled in suitable containers and 10 lyophilized. The lyophilized analyte containing matrix is reconstituted by adding one liter of a diluent containing 65 grams of BSA, 25 grams of NaCl, protease inhibitor, and about 0.4 grams of NAC.

Alternatively, one liter of the matrix may be prepared by 15 dissolving about 100 grams of BSA, about one gram of gelatin, about 40 grams of sodium chloride, 3 grams of EDTA, a preservative, and 0.4 grams of NAC and a clinically appropriate level of the analyte or analyte analogue in 700 ml of 0.50m sodium phosphate. After all ingredients are 20 dissolved the pH is adjusted to 7.0 and then a sufficient volume of a buffer, such as sodium phosphate is added to bring the volume to 1.0L. The liquid may be aliquoted and stored refrigerated or frozen. If the liquid is to be frozen, bulking agents are also added.

25 Surprisingly for the troponin I analyte, troponin I fragments also have increased stability. This is surprising because the stability of the troponin I fragments was found to be less than that of the full length troponin I when the

matrix is normal human serum. In addition, certain troponin I fragments had similar binding to the anti-troponin antibody used in the assay when compared with the full length troponin I molecule.

5 Thus, the present invention has many advantages over the prior art. The matrix is non-human serum derived which prevents the user (and manufacturing personnel) from exposure to many of the diseases which can be spread by contact with human blood products. The matrix is also able to keep the
10 analyte stable in liquid form for an extended period of time. Current formulations can also be lyophilized or frozen and can be reliably reconstituted or thawed for up to at least nine months shelf storage with very little variation in calibration. After reconstitution or thawing, the analyte is
15 stable for up to three weeks at 2-8C. Spiking of the analyte into the matrix yields a calibration curve which closely parallels a human serum curve. Non-specific binding levels in the "synthetic" matrix also closely parallel the levels seen in normal human serum. Moreover, fragments such as
20 recombinantly or synthetically produced peptide fragments of proteins can be utilized instead of full length proteins. Indeed these fragments are preferred because of their stability in the matrix coupled with the availability and reproducibility of the recombinantly or synthetically produced
25 fragments. The analyte analogue (e.g. the fragment) should have binding characteristics similar to that of the full length marker. Methods to determine and map epitope sites are known to those skilled in the art as is the art of producing antibodies against a specific antigen.

It is to be understood that the matrix of the present invention can be used for many analytes but it is particularly useful when the analyte is an unstable and/or relatively insoluble protein such as the cardiac markers, in particular
5 troponin and CK-MB.

Example 1**Preparation of a Calibrator/Control Matrix**

To about seven hundred milliliters of purified water was
5 added with stirring about three grams of EDTA (stirred until dissolved), then about 40.0 grams of sodium chloride, about 6.9 grams of sodium phosphate, monobasic, about 0.424 mgs of NAC, about 50 grams of trehalose, about 3.3 milliliters of a stock solution of chloramphenicol to provide a final
10 concentration of 165 mg/mL, about 0.75 milliliters of a stock solution of clortrimazole to provide a final concentration of 3 ppms, about 10 milliliters of a 1% aqueous solution of gelatin, then stirring slowly, about 95 grams of protease free bovine serum albumin until dissolved), and 2 milliliters of a
15 25% solution of sodium azide. The pH was adjusted to 7.3 and the total volume was adjusted to 1 liter with purified water.
The final matrix may be sterile filtered.

Example 2**Preparation of a Lyophilized Calibrator/Control Matrix**

To about seven hundred milliliters of purified water is added about three grams of EDTA, about 15 grams of sodium chloride, about 7 grams of sodium phosphate, monobasic, about
25 50 grams of trehalose, about 3.3 milliliters of a stock solution of chloramphenicol to provide a final concentration of 165 mg/mL, about 0.75 milliliters of a stock solution of clortrimazole to provide a final concentration of 3 ppms, about 10 milliliters of a 1% aqueous solution of gelatin, and

about 30 grams of bovine serum albumin. The pH is adjusted to 5.5 and the total volume is adjusted to 1 liter with purified water. The final matrix is sterile filtered and lyophilized.

- A reconstitution diluent of one liter is prepared by
- 5 combining in aqueous solution about 65 grams of albumin, 25 grams of sodium chloride and 0.4 grams of NAC, protease inhibitor and about 2 milliliters of a 25% solution of sodium azide.

10 Example 3

Preparation of a Calibrator/Control Matrix

- To about seven hundred milliliters of purified water is added about five grams of EDTA, about 50 grams of sodium
- 15 chloride, about 7 grams of sodium phosphate, monobasic, about 0.4 mgs of NAC, about 3.3 milliliters of a stock solution of chloramphenicol to provide a final concentration of 165 mg/mL, about 0.75 milliliters of a stock solution of clotrimazole to provide a final concentration of 3 ppms, about 10 milliliters
- 20 of a 1% aqueous solution of gelatin, and about 95 grams of protease free bovine serum albumin. The pH is adjusted to 6.5 and the total volume is adjusted to 1 liter with purified water. The final matrix may be sterile filtered.

Example 4**Preparation of Calibrators using a recombinant protein**

A stock solution of human recombinant troponin I was prepared in polypropylene labware by adding a sufficient amount of recombinant troponin I so that calibrators or controls can be made that have concentrations ranging from about 0 to 100 ng/mL of troponin I.

In one experiment solutions of troponin I were prepared by adding a sufficient amount of an unpurified solution of recombinant troponin I at 100 ug/mL to the following matrices:

Normal human serum, plasma, and a matrix similar to that described in Example 1. For each matrix the final volume was 15 milliliters of a 100 ng/mL solution of recombinant troponin I. The recombinant troponin I had the following sequence:

15 MADGSSDAAREPRPAPAPIRRSSNYRAYATEPHAKKKSKISASRKLQLKTL
REAEERRGEKGRALSTRCQPLELTGLGFAELQDLCRQLHARVDKVDEERYDIEAKVTKNITE
IADLTQKIFDLRGKFKRPTLRRVRISADAMMQALLGARAKESLDLRAHLKQVKKEDTEKENR
EVGDWRKNIDALSGMEGRKKKKFEES (SEQ ID NO: 1) and included a 6 His carboxy terminus tail and a seven amino acid sequence from the 20 phage T7 Gene 10 leader sequence at the amino terminus. See, also Vallins W.J. et al., Molecular cloning of human cardiac troponin I using polymerase chain reaction, FEBS LETTERS :Vol. 270, number 1, 2 September 1990.

Aliquots of each of the three troponin I solutions were stored at 2-8 C and evaluated for stability. On each day of the evaluation an aliquot of each troponin I solution was

analyzed on a Stratus II Fluorometric Analyzer. The Stratus II Fluorometric Analyzer is sold by Dade International Inc. For principles of operation of the analyzer and immunoassay see for instance U.S. Patent No. 4,517,288 incorporated herein 5 by reference and Giegle et al. Clinical Chemistry 28:1894-1898 (1982). The analyzer measures the rate of change of a fluorescent signal. Generally, an antibody to an analyte, such as troponin I, is pre-immobilized on a solid phase of glass fiber filter paper. For troponin I, an aliquot of each 10 troponin I solution is applied to the antibody and immunologically binds to the antibody to form a reaction zone. Next, a conjugate of alkaline phosphatase-anti-troponin I antibody is added to the reaction zone. The conjugate binds to the troponin I. A substrate wash solution containing 4 15 methyl umbelliferyl phosphate is applied to the reaction zone. A front surface fluorometer measures the rate of change of fluorescence in rate units designated as millivolts per minute (mvm).

The results of the evaluation can be seen in Figure 1. 20 As can be seen from Figure 1, the matrix of the present invention provided more stability to the troponin-I analyte than normal human serum or plasma.

Example 5

25 Preparation of Calibrators using a recombinantly produced peptide

A stock solution of human recombinant troponin I peptide is prepared in polypropylene labware by adding a

sufficient amount of a recombinant troponin I peptide so that calibrators or controls can be made that have concentrations ranging from about 0 to 100 ng/mL of troponin I.

In one experiment solutions of troponin I were prepared
5 by adding a sufficient amount of a recombinant 80 amino acid peptide of recombinant troponin I having the sequence
ADGSSDAAREPRPAPAPIRRSSNYRAYATEPHAKKSKISASRKLQLKTLLLQIAKQELER
EAEERRGEKGRALSTRCQ (SEQ ID NO: 2) also having a six histidine tail at the carboxy terminus and seven amino acids from the
10 phage T7 Gene 10 leader sequence at the amino terminus (see,
also Vallins W.J. et al., Molecular cloning of human cardiac troponin I using polymerase chain reaction, FEBS LETTERS :Vol.
270, number 1, 2 September 1990)
at 7500 ng/mL to the following matrices:

15 Normal human serum, processed human plasma, plasma, and a matrix similar to that described in Example 1 to provide a 100 ng/mL solution of recombinant troponin I peptide in each matrix.

Aliquots of each of the four troponin I solutions were
20 stored at 2-8 C and evaluated for stability. On each day of the evaluation an aliquot of each troponin I solution was analyzed on a Stratus II Fluorometric Analyzer. The Stratus II Fluorometric Analyzer is sold by Dade International Inc. For principles of operation of the analyzer and immunoassay
25 see for instance U.S. Patent No. 4,517,288 incorporated herein by reference and Giegle et al. Clinical Chemistry 28:1894-1898 (1982). The analyzer measures the rate of change of a fluorescent signal. Generally,

an antibody to an analyte, such as troponin I, is pre-immobilized on a solid phase of glass fiber filter paper. For troponin I, an aliquot of each troponin I solution is applied to the antibody and immunologically binds to the antibody to 5 form a reaction zone. Next, a conjugate of alkaline phosphatase-anti-troponin I antibody is added to the reaction zone. The conjugate binds to the troponin I. A substrate wash solution containing 4 methyl umbelliferyl phosphate is applied to the reaction zone. A front surface fluorometer 10 measures the rate of change of fluorescence in rate units designated as millivolts per minute (mvm).

The results of the evaluation can be seen in Figure 2. As can be seen from Figure 2, the matrix of the present invention provided more stability to the troponin-I analyte 15 than normal human serum, processed human plasma (PHP) or plasma.

Example 6

20

Preparation of Calibrators using a synthetic peptide

A stock solution of a synthetic peptide of troponin I is prepared in polypropylene labware by adding a sufficient amount of the peptide so that calibrators or controls can be 25 made that have concentrations ranging from about 0 to 50 ng/mL of troponin I.

In one experiment solutions of troponin I were prepared by adding a sufficient amount of a synthetic peptide of troponin I having the sequence

RAYATEPHAKKSKISASRKLQLKTLLQIAKQEL (SEQ ID NO: 3)

5 at a stock concentration (in purified water) of 1.4 mg/mL to the following matrices:

Normal human serum, plasma, processed human plasma, a synthetic matrix at pH 7.6 containing 100 mM Tris, 150 mM NaCl, 0.1% Gelatin, 2% BSA, 0.1% Sodium Azide, and 0.1% Zonyl 10 fluorosurfactant (DXMC) and a matrix similar to that described in Example 1 to provide 50 ng/mL solution of troponin I in each matrix and a 10 ng/mL solution of troponin I.

Aliquots of each of the four troponin I solutions were stored at 2-8 C and evaluated for stability. On each day of 15 the evaluation an aliquot of each troponin I solution was analyzed on a Stratus II Fluorometric Analyzer. The Stratus II Fluorometric Analyzer is sold by Dade International Inc. For principles of operation of the analyzer and immunoassay see for instance U.S. Patent No. 4,517,288 incorporated herein 20 by reference and Giegle et al. Clinical Chemistry 28:1894-1898 (1982). The analyzer measures the rate of change of a fluorescent signal. Generally, an antibody to an analyte, such as troponin I, is pre-immobilized on a solid phase of glass fiber filter paper. For troponin I, an aliquot of each 25 troponin I solution is applied to the antibody and immunologically binds to the antibody to form a reaction zone. Next, a conjugate of alkaline phosphatase-

anti-troponin I antibody is added to the reaction zone. The conjugate binds to the troponin I. A substrate wash solution containing 4 methyl umbelliferyl phosphate is applied to the reaction zone. A front surface fluorometer measures the rate 5 of change of fluorescence.

The results of the evaluation can be seen in Figures 3 and 4. As can be seen from Figures 3 and 4, the matrix of the present invention provided more stability to the troponin-I analyte analogue than normal human serum, processed human 10 plasma (PHP), the synthetic base DXMC, or plasma.

Example 7

Preparation of Calibrators using a synthetic peptide

15 A stock solution of a synthetic peptide of troponin I is prepared in polypropylene labware by adding a sufficient amount of the peptide so that calibrators or controls can be made that have concentrations ranging from about 0 to 100 ng/mL of troponin I.

20 In one experiment solutions of 40 ug/mL troponin I were prepared by adding a sufficient amount of a synthetic peptide of troponin I having the sequence
RAYATEPHAKKKSKISASRKLQLKTLQIAKQEL (SEQ ID NO: 4)
to the following matrices:

25 Normal human serum, plasma, and a matrix similar to that described in Example 1 (except that the pH of the synthetic matrix was adjusted to 5.5) to provide 3.0

milliliters of a 100 ng/mL solution of troponin I in each matrix. In addition, EDTA was added to each matrix at about 3.5 mg/mL.

A second set of solutions was prepared as above, except
5 that the solutions also contained a protease inhibitor cocktail of PEPSTATIN at 680 ng/mL and aminoethylbenzenesulfonyl fluoride at 208 ug/mL.

Aliquots of each of the six troponin I solution were stored at 37 C and evaluated for stability. On each day of
10 the evaluation an aliquot of each troponin I solution was analyzed on a Stratus II Fluorometric Analyzer. The Stratus II Fluorometric Analyzer is sold by Dade International Inc. For principles of operation of the analyzer and immunoassay see for instance U.S. Patent No. 4,517,288 incorporated herein
15 by reference and Giegle et al. Clinical Chemistry 28:1894-1898 (1982). The analyzer measures the rate of change of a fluorescent signal. Generally, an antibody to an analyte, such as troponin I, is pre-immobilized on a solid phase of glass fiber filter paper. For troponin I, an aliquot of each
20 troponin I solution is applied to the antibody and immunologically binds to the antibody to form a reaction zone. Next, a conjugate of alkaline phosphatase-anti-troponin I antibody is added to the reaction zone. The conjugate binds to the troponin I. A substrate wash solution containing 4
25 methyl umbelliferyl phosphate is applied to the reaction zone. A front surface fluorometer measures the rate of change of fluorescence in rate units designated as millivolts per minute (mvm).

The results of the evaluation can be seen corresponding to Figures 5 and 6. As can be seen from Figures 5 and 6, the matrix of the present invention provided more stability to the troponin-I analyte analogue than normal human serum, or plasma
5 with or without the protease inhibitors.

Example 8

10 Performing an Immunoassay using Troponin I Calibrators and Controls

A stock solution of a synthetic peptide of troponin I is prepared in polypropylene labware by adding a sufficient
15 amount of the peptide so that calibrators or controls can be made that have concentrations ranging from about 0 to 50 ng/mL of troponin I.

In one experiment solutions of troponin I were prepared by adding a sufficient amount of a synthetic peptide of
20 troponin I having the sequence

RAYATEPHAKKSKISASRKLQLKTLLQIAKQEL (SEQ ID NO: 5)
at a stock concentration of 1.4 mg/mL to a matrix similar to that described in Example 1 to provide calibrator solutions of troponin I having the following concentrations: 0 ng/mL, 2
25 ng/mL, 8 ng/mL, 15 ng/mL, 25 ng/mL and 50 ng/mL. Controls were prepared in a similar fashion to provide control solutions at about 4 ng/mL, 20 ng/mL and 35 ng/mL.

Aliquots of each of the troponin I solutions were stored frozen. Frozen solutions were thawed and a calibration curve was generated. The controls prepared as discussed above and controls prepared from normal human serum were also evaluated.

5 The range for the normal human serum controls was 2.1 -2.9 ng/mL for the low control and 15.9-21.5 for the high control. Duplicate samples of each troponin I solution was analyzed on a Stratus II Fluorometric Analyzer and a calibration curve was generated. The Stratus II Fluorometric Analyzer is sold by

10 Dade International Inc. For principles of operation of the analyzer and immunoassay see for instance U.S. Patent No. 4,517,288 incorporated herein by reference and Giegle et al. Clinical Chemistry 28:1894-1898 (1982). The analyzer measures the rate of change of a fluorescent signal. An antibody to an

15 analyte, such as troponin I, is pre-immobilized on a solid phase of glass fiber filter paper. An aliquot of each troponin I solution is applied to the antibody and immunologically binds to the antibody to form a reaction zone. Next, a conjugate of alkaline phosphatase-anti-troponin I

20 antibody is added to the reaction zone. The conjugate binds to the troponin I. A substrate wash solution containing 4 methyl umbelliferyl phosphate is applied to the reaction zone. A front surface fluorometer measures the rate of change of fluorescence in rate units designated as millivolts per minute

25 (mVm).

The results of the calibration in millivolts per minute (mvm) can be seen in Table 1 and the calibration curve is presented graphically in Figure 6.

Calibrator Level	Rate 1 (mV/m)	Rate 2 (mV/m)	Mean
0	171.5	180.4	176.0
2	463.7	464.5	464.1
8	1287.5	1208.5	1248.0
15	2487.6	2481.9	2484.8
25	3926.6	3826.6	3876.6
50	7668.0	6767.0	7217.5

Table 1

5 Control recoveries are presented in Table 2.

Control	Rep. 1 (ng/mL)	Rep. 2 (ng/mL)	Rep. 3 (ng/mL)	Rep. 4 (ng/mL)	Mean
Syn. Low	3.7	3.6			3.7
Syn. Mid	17.1	16.3			16.7
Syn. Hi	32.6	32.8			32.7
Serum Lo	2.6	2.5	2.5	2.3	2.5
Serum Hi	18.2	18.7	19.7	18.0	18.7

Table 2

10 Example 9

Preparing CK-MB Calibrators/Controls

A stock solution of CK-MB is prepared by adding a sufficient amount of the CK-MB so that calibrators or controls can be made that have concentrations ranging from about 0 to 125 ng/mL of CK-MB.

- 5 Solutions of CK-MB are prepared by adding a sufficient amount of CK-MB to a matrix similar to that described in Example 1 to provide calibrator solutions of CK-MB having the following concentrations: 0, 4, 10, 25, 60 and 125 ng/mL. Controls are prepared in a similar fashion

10

Example 10

Preparing Troponin T Calibrators/Controls

- 15 A stock solution of Troponin T is prepared by adding a sufficient amount of the Troponin T so that calibrators or controls can be made that have concentrations ranging from about 0 to 12 ng/mL of Troponin T.

- Solutions of Troponin T are prepared by adding a
20 sufficient amount of Troponin T to a matrix similar to that described in Example 1 to provide calibrator solutions of Troponin T having the following concentrations: 0, 1, 2, 4, 8, and 12 ng/mL. Controls are prepared in a similar fashion

25 **Example 11**

Stability of Calibrators at 4C

A study was conducted to determine the stability of calibrators prepared similarly to the calibrators prepared

in Example 6. Immunoassay kits, which included calibrators, were prepared and stored at about 4 C and evaluated on a Stratus II Fluorometric Analyzer. On each day of the evaluation calibration curves were generated using unopened vials of calibrators and controls and a patient pool to determine if the controls and patient pool (both stored at -70 C and freshly thawed prior to use) recovered within the expected ranges. The ranges of the controls and patient pool had been previously established by obtaining at least 80 replicates of each control level and patient pool. The control limits were set at +/- 2 standard deviations or 15% of the mean, whichever was larger. All of the assay components, thus the calibrators, were determined to be acceptable if the duplicates of each control and patient pool were within 12% of and if the mean of the duplicates fell within the calculated range. The assay kit, thus the calibrators, were found to be acceptable for at least 60 days. A second study conducted similarly confirmed the results.

20 **Example 12**

Stability of Calibrators at 25C

Two studies were conducted similarly to that described in Example 11, except that the kit reagents were stored at 25C instead of 4C. The kits, thus the calibrators, were found to be stable for at least about 7-14 days.

Example 13

Stability of Calibrators at 2 to 8C/-70C

A study was conducted similarly to that described in Example 11, except that the calibrators at 2 ng/mL and 25 ng/mL were also stored at -70C. The recovery of the frozen
5 calibrators was determined and compared to calibrators stored at 4C. A ratio of the 2-8 C/-70 C was determined. The calibrators at -70 C, were found to be stable for at least 60 days. A second study conducted similarly confirmed the results.

10 In another study, the recovery of a patient pool (stored and used as described above in Example 11 with an established recovery range also as described above in Example 11) against a calibration curve generated from calibrators stored at -70 C was determined. The calibrators were found to be stable for
15 at least 100 days.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Flaa, Cathy
Sabucedo, Alberto
Chin, Bruce
Bauer, Roger

(ii) TITLE OF INVENTION: COMPOSITION FOR STABILIZING PROTEINS
AND PROTEIN FRAGMENTS

(iii) NUMBER OF SEQUENCES: 7

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: DADE INTERNATIONAL INC.
(B) STREET: 1717 Deerfield Road
(C) CITY: Deerfield
(D) STATE: Illinois
(E) COUNTRY: US
(F) ZIP: 60015

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: MICROSOFT WORD 2.0

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: US 08/400,158
(B) FILING DATE: 07-MARCH-1995
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER:
(B) FILINF DATE:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Tymeson, Cynthia G.
(B) REGISTRATION NUMBER: 34,745
(C) REFERENCE/DOCKET NUMBER: DA-9000

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (305) 222-6423
(B) TELEFAX: (305) 222-6686
(C) TELEX:

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 210
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single stranded
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE:
 - (A) DESCRIPTION:
- (iii) HYPOTHETICAL: no
- (iv) ANTI-SENSE: no
- (v) FRAGMENT TYPE:
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM:
 - (B) STRAIN:
 - (C) INDIVIDUAL ISOLATE:
- (vii) IMMEDIATE SOURCE:
 - (A) LIBRARY:
 - (B) CLONE:
- (viii) POSITION IN GENOME:
 - (A) CHROMOSOME SEGMENT
- (ix) FEATURE:
 - (A) NAME/KEY:
- (x) PUBLICATION INFORMATION:
 - (A) AUTHORS: Vallins W.J. et al.
 - (B) TITLE: Molecular Cloning of Human Cardiac Troponin I Using Polymerase Chain Reaction
 - (C) JOURNAL: FEBS LETTERS
 - (D) VOLUME: 270
 - (E) ISSUE: 1,2
 - (F) PAGES: 57-61
 - (G) DATE: September 1990

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Met Ala Asp Gly Ser Ser Asp Ala Ala Arg Glu Pro Arg Pro Ala Pro
1 5 10 15

Ala Pro Ile Arg Arg Arg Ser Ser Asn Tyr Arg Ala Tyr Ala Thr Glu
20 25 30

Pro His Ala Lys Lys Lys Ser Lys Ile Ser Ala Ser Arg Lys Leu Gln
35 40 45

Leu Lys Thr Leu Leu Leu Gln Ile Ala Lys Gln Glu Leu Glu Arg Glu
50 55 60

Ala Glu Glu Arg Arg Gly Glu Lys Gly Arg Ala Leu Ser Thr Arg Cys
65 70 75 80

Gln Pro Leu Glu Leu Thr Gly Leu Gly Phe Ala Glu Leu Gln Asp Leu
85 90 95

Cys Arg Gln Leu His Ala Arg Val Asp Lys Val Asp Glu Glu Arg Tyr
100 105 110

Asp Ile Glu Ala Lys Val Thr Lys Asn Ile Thr Glu Ile Ala Asp Leu
115 120 125

Thr Gln Lys Ile Phe Asp Leu Arg Gly Lys Phe Lys Arg Pro Thr Leu
130 135 140

Arg Arg Val Arg Ile Ser Ala Asp Ala Met Met Gln Ala Leu Leu Gly
145 150 155 160

Ala Arg Ala Lys Glu Ser Leu Asp Leu Arg Ala His Leu Lys Gln Val
165 170 175

Lys Lys Glu Asp Thr Glu Lys Glu Asn Arg Glu Val Gly Asp Trp Arg
180 185 190

Lys Asn Ile Asp Ala Leu Ser Gly Met Glu Gly Arg Lys Lys Lys Phe
195 200 205

Glu Ser
210

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 80
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single stranded
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE:

- (A) DESCRIPTION:

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

- (A) ORGANISM:
- (B) STRAIN:
- (C) INDIVIDUAL ISOLATE:

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY:
- (B) CLONE:

(viii) POSITION IN GENOME:

- (A) CHROMOSOME SEGMENT

(ix) FEATURE:

- (A) NAME/KEY:

(x) PUBLICATION INFORMATION:

- (A) AUTHORS: Vallins W.J. et al.
- (B) TITLE: Molecular Cloning of Human Cardiac Troponin I Using Polymerase Chain Reaction
- (C) JOURNAL: FEBS LETTERS
- (D) VOLUME: 270
- (E) ISSUE: 1,2
- (F) PAGES: 57-61
- (G) DATE: September 1990

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Ala Asp Gly Ser Ser Asp Ala Ala Arg Glu Pro Arg Pro Ala Pro Ala
1 5 10 15

Pro Ile Arg Arg Arg Ser Ser Asn Tyr Arg Ala Tyr Ala Thr Glu Pro
20 25 30

His Ala Lys Lys Lys Ser Lys Ile Ser Ala Ser Arg Lys Leu Gln Leu
35 40 45

Lys Thr Leu Leu Leu Gln Ile Ala Lys Gln Glu Leu Glu Arg Glu Ala
50 55 60

Glu Glu Arg Arg Gly Glu Lys Gly Arg Ala Leu Ser Thr Arg Cys Gln
65 70 75 80

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 35
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single stranded
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE:

- (A) DESCRIPTION:

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

- (A) ORGANISM:
- (B) STRAIN:
- (C) INDIVIDUAL ISOLATE:

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY:
- (B) CLONE:

(viii) POSITION IN GENOME:

- (A) CHROMOSOME SEGMENT

(ix) FEATURE:

- (A) NAME/KEY:

(x) PUBLICATION INFORMATION:

- (A) AUTHORS:
- (B) TITLE:
- (C) JOURNAL:
- (D) VOLUME:
- (E) ISSUE:
- (F) PAGES:
- (G) DATE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

Arg Ala Tyr Ala Thr Glu Pro His Ala Lys Lys Lys Ser Lys Ile Ser
1 5 10 15

Ala Ser Arg Lys Leu Gln Leu Lys Thr Leu Leu Leu Gln Ile Ala Lys
20 25 30

Gln Glu Leu
35

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 35
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single stranded
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE:

- (A) DESCRIPTION:

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

- (A) ORGANISM:
- (B) STRAIN:
- (C) INDIVIDUAL ISOLATE:

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY:
- (B) CLONE:

(viii) POSITION IN GENOME:

- (A) CHROMOSOME SEGMENT

(ix) FEATURE:

(A) NAME/KEY:

(x) PUBLICATION INFORMATION:

(A) AUTHORS:

(B) TITLE:

(C) JOURNAL:

(D) VOLUME:

(E) ISSUE:

(F) PAGES:

(G) DATE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Arg Ala Tyr Ala Thr Glu Pro His Ala Lys Lys Lys Ser Lys Ile Ser
1 5 10 15

Ala Ser Arg Lys Leu Gln Leu Lys Thr Leu Leu Leu Gln Ile Ala Lys
20 25 30

Gln Glu Leu
35

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 35

(B) TYPE: amino acid

(C) STRANDEDNESS: single stranded

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE:

(A) DESCRIPTION:

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(A) ORGANISM:

(B) STRAIN:

(C) INDIVIDUAL ISOLATE:

(vii) IMMEDIATE SOURCE:

(A) LIBRARY:

(B) CLONE:

(viii) POSITION IN GENOME:

(A) CHROMOSOME SEGMENT

(ix) FEATURE:

(A) NAME/KEY:

(x) PUBLICATION INFORMATION:

(A) AUTHORS:

(B) TITLE:

(C) JOURNAL:

(D) VOLUME:

(E) ISSUE:

(F) PAGES:

(G) DATE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

Arg Ala Tyr Ala Thr Glu Pro His Ala Lys Lys Lys Ser Lys Ile Ser
1 5 10 15

Ala Ser Arg Lys Leu Gln Leu Lys Thr Leu Leu Leu Gln Ile Ala Lys
20 25 30

Gln Glu Leu
35

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 35

(B) TYPE: amino acid

(C) STRANDEDNESS:single stranded

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE:

(A) DESCRIPTION:

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(A) ORGANISM:

(B) STRAIN:

(C) INDIVIDUAL ISOLATE:

40

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY:
- (B) CLONE:

(viii) POSITION IN GENOME:

- (A) CHROMOSOME SEGMENT

(ix) FEATURE:

- (A) NAME/KEY:

(x) PUBLICATION INFORMATION:

- (A) AUTHORS:
- (B) TITLE:
- (C) JOURNAL:
- (D) VOLUME:
- (E) ISSUE:
- (F) PAGES:
- (G) DATE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Arg Ala Tyr Ala Thr Glu Pro His Ala Lys Lys Lys Ser Lys Ile Ser
1 5 10 15

Ala Ser Arg Lys Leu Gln Leu Lys Thr Leu Leu Leu Gln Ile Ala Lys
20 25 30

Gln Glu Leu
35

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 80
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single stranded
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE:

- (A) DESCRIPTION:

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

- (A) ORGANISM:

(B) STRAIN:
(C) INDIVIDUAL ISOLATE:

(vii) IMMEDIATE SOURCE:

(A) LIBRARY:
(B) CLONE:

(viii) POSITION IN GENOME:

(A) CHROMOSOME SEGMENT

(ix) FEATURE:

(A) NAME/KEY:

(x) PUBLICATION INFORMATION:

(A) AUTHORS:
(B) TITLE:
(C) JOURNAL:
(D) VOLUME:
(E) ISSUE:
(F) PAGES:
(G) DATE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

Ala Asp Gly Ser Ser Asp Ala Ala Arg Glu Pro Arg Pro Ala Pro Ala
1 5 10 15

Pro Ile Arg Arg Arg Ser Ser Asn Tyr Arg Ala Tyr Ala Thr Glu Pro
20 25 30

His Ala Lys Lys Lys Ser Lys Ile Ser Ala Ser Arg Lys Leu Gln Leu
35 40 45

Lys Thr Leu Leu Leu Gln Ile Ala Lys Gln Glu Leu Glu Arg Glu Ala
50 55 60

Glu Glu Arg Arg Gly Glu Lys Gly Arg Ala Leu Ser Thr Arg Cys Gln
65 70 75 80

We claim:

Claim 1. A liquid composition for stabilizing proteins and
5 protein fragments or analytes comprising:

- a. a buffer;
- b. a reducing agent;
- c. a stabilizing protein;
- 10 d. a chelating agent; and
- e. a salt.

Claim 2. The composition of claim 1 wherein the analyte is
a cardiac marker or a fragment thereof.

15 Claim 3. The composition of claim 1 wherein the analyte is
troponin or a fragment thereof.

Claim 4. The composition of claim 1 wherein the analyte is
20 troponin I or a fragment thereof.

Claim 5. The composition of claim 1 wherein the analyte is
RAYATEPHAKKSKISASRKLQLKTLLLQIAKQEL (SEQ ID NO: 6).

25 Claim 6. The composition of claim 1 wherein the analyte is
ADGSSDAAREPRPAPAPIRRSSNYRAYATEPHAKKSKISASRKLQLKTLLLQIAKQEL
EREAEERRGEKGRALSTRCQ (SEQ ID NO: 7).

Claim 7. The composition of claim 1 further comprising a blocking agent.

Claim 8. The composition of claim 1 wherein the composition
5 further comprises a bulking agent.

Claim 9. The composition of claim 8 wherein the composition
is lyophilized.

10 Claim 10. The composition of claim 1 wherein the composition
is frozen.

Claim 11. The composition of claim 1 wherein the protein
stabilizer is an albumin.

15

Claim 12. The composition of claim 11 wherein the albumin
is protease free.

20 Claim 13. The composition of claim 7 wherein the blocking
agent is gelatin.

Claim 14. The composition of claim 8 wherein the bulking
agent is selected from the group of bulking agents
consisting of trehalose, glucose, sucrose, galactose,
25 manose, maltose, lactose, isomaltose, cellobiose,
mannobiose, melbiose, maltotriose, nystose, maltotetraose,
maltopentaose, maltohexaose, and maltoheptaose.

Claim 15. A composition for stabilizing proteins and protein fragments or analytes comprising:

- a. a buffer;
- 5 b. a reducing agent selected from the group consisting of N-acetyl-cysteine, 2-aminoethanethiol, 2-mercaptopropanol, 2-mercaptopropylamine and dithiothreitol.;
- c. a stabilizing protein selected from the group of albumin, ovalbumin and casein;
- 10 d. a chelating agent selected from the group consisting of ethylenebis (oxyethylene nitrilio)-tetraacetic acid (EGTA), ethylene diamine tetracetic acid (EDTA), citrates, or oxalates; and
- e. a salt.

15

Claim 16. The composition of claim 15 further comprising a blocking agent.

20 Claim 17. The composition of claim 15 wherein the composition further comprises a bulking agent.

Claim 18. The composition of claim 17 wherein the composition is lyophilized.

25 Claim 19. The composition of claim 15 wherein the composition is frozen.

Claim 20. The composition of claim 15 wherein the protein stabilizer is albumin.

Claim 21. The composition of claim 20 wherein the albumin is protease free.

5 Claim 22. The composition of claim 16 wherein the blocking agent is gelatin.

Claim 23. The composition of claim 17 wherein the bulking agent is selected from the group of bulking agents
10 consisting of trehalose, glucose, sucrose, galactose, manose, maltose, lactose, isomaltose, cellobiose, mannobiose, melbiose, maltotriose, nystose, maltotetraose, maltopentaose, maltohexaose, and maltoheptaose.

15 Claim 24. A method to prepare a non-human serum based aqueous solution for stabilizing proteins or protein fragments the method comprising:
combining in solution effective amounts of a buffer, reducing agent, a stabilizing protein, a chelating agent and
20 a salt.

Claim 25. A liquid non-human serum based solution for stabilizing proteins or protein fragments prepared by the method comprising: combining in solution effective amounts
25 of a buffer, reducing agent, a stabilizing protein, a chelating agent and a salt.

1 / 7

Figure 1




Figure 2





Figure 3


Figure 4

Figure 5




Figure 6





Figure 7

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 96/03034

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 C12N9/96 G01N33/68 G01N33/531

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 6 C12N G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP,A,0 528 499 (EASTMAN KODAK CO) 24 February 1993	1,2, 9-12,14, 15, 17-21, 23-25
Y	see column 5, line 3 - line 11 see the whole document	3-8,13, 16,22
Y	--- US,A,4 931 385 (BLOCK ELLIOTT ET AL) 5 June 1990 see claims 10-B	3-8,13, 16,22
Y	--- DE,A,44 05 249 (PASTEUR SANOFI DIAGNOSTICS) 25 August 1994 see the whole document	3-6
	---	-/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

1

Date of the actual completion of the international search	Date of mailing of the international search report
18 July 1996	06.08.96
Name and mailing address of the ISA European Patent Office, P.O. 5818 Patentlaan 2 NL - 2280 HV Rijswijk • Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax (+31-70) 340-3016	Authorized officer Hoekstra, S

INTERNATIONAL SEARCH REPORT

International Application No

PCT, US 96/03034

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CALBIOCHEM CATALOGUE, 1994 - 1995, XP002008720 Albumins, Bovine Serum; selecting a BSA for Your application. Fibroblast growth factor, Basic, Human, recombinant... see composition of sterile filtered soltn. Creatitine phosphokinase, see solution it is provided in. ---	1-22
A	H.U. BERGMEYER: "Methods of enzymatic analysis", VERLAG CHEMIE , 1986 XP002008721 Vol. III Enzymes 1:Oxidoreductases, transferases, Ch. 7.4 Creatine Kinase (W. Gerhardt). see page 508 - page 518 ---	1-22
A	M.P. DEUTSCHER: "Methods in Enzymology, vol. 82: Guide to protein purification." , ACADEMIC PRESS, INC. , 1990 XP002008722 see page 83 - page 89 See e.g. paragraph bridging pp85 and 86 -----	1-22

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT, US 96/03034

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-0528499	24-02-93	US-A-	5217890	08-06-93
		CA-A,C	2073546	21-02-93
		JP-A-	5207880	20-08-93
US-A-4931385	05-06-90	US-A-	5102788	07-04-92
DE-A-4405249	25-08-94	FR-A-	2701954	02-09-94
		CA-A-	2116066	24-08-94
		GB-A-	2275774	07-09-94
		JP-A-	6265546	22-09-94